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Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of
rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer.
Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated
with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point
was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.
Results: In all, 45 patients were treated with single-agent ridaforolimus. Clinical benefit was achieved by 13 patients (29%),
including 5 (11%) with confirmed partial responses and 8 (18%) with prolonged stable disease. All patients with clinical benefit
response received ridaforolimus for more than 4 months. In this heavily pretreated population, the 6-month progression-free
survival was 18%. Ridaforolimus was generally well tolerated: adverse events were predictable and manageable, consistent with
prior studies in other malignancies. Overall, the most common adverse events were diarrhoea (58%) and mouth sores (56%); most
common grade 3 or higher adverse events were anaemia (27%) and hyperglycaemia (11%).
Conclusion: Single-agent ridaforolimus has antitumor activity and acceptable tolerability in advanced endometrial cancer
patients. Further clinical evaluation of ridaforolimus is warranted.
More than 46 000 new cases of endometrial cancer were diagnosed
in the United States in 2011, with nearly 8100 deaths (Siegel et al,
2011). Deaths due to endometrial cancer have been on the rise,
with the rate doubling over the past 20 years (Sorosky, 2008). Most
deaths are due to metastatic or recurrent disease, where survival is
poor even with current standard chemotherapy (Pectasides et al,
2007). Response rates with first-line chemotherapy in women with
advanced or recurrent endometrial cancer are low, ranging from 20
to 30% for single agents and up to 40 to 60% for combination
regimens (Fleming, 2007; Pectasides et al, 2007; Dellinger and
Monk, 2009). For women with advanced disease, efficacy after
first-line taxane-based regimens is extremely poor (Dellinger and
Monk, 2009; Dizon, 2010). Improved treatment options are needed
with an increased emphasis on improving the therapeutic index.
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The mammalian target of rapamycin (mTOR) is a downstream
effector of the phosphoinositide 3-kinase (PI3K)/AKT pathway
and thereby serves as a key regulator of cell growth and division
(Dancey, 2010; Shorning et al, 2011). Many tumours, including
endometrial cancer, have dysregulated PI3K/AKT function (Dedes
et al, 2011). Loss of function of the tumour suppressor phosphatase
and tensin homologue (PTEN) and gain-of-function mutations of
the PIK3CA gene, both of which increase activity of the PI3K/AKT
pathway, have been reported in endometrial cancer patients
(Salvesen et al, 2004; Hayes et al, 2006; Janku et al, 2011).
Moreover, activation of the PI3K pathway in uterine epithelium via
biallelic loss of PTEN or selective AKT activation appears to be
sufficient for initiating endometrial cancer in preclinical models
(Daikoku et al, 2008; Memarzadeh et al, 2010). On the basis of
these observations, mTOR inhibition may provide a rational
approach to treatment of endometrial cancer.
Several mTOR inhibitors, including rapamycin and its analo-
gues everolimus, temsirolimus, and ridaforolimus, have been
evaluated in cancer patients (Choi et al, 2010). Both everolimus
and temsirolimus have shown promising results in patients with
advanced or recurrent endometrial cancer (Slomovitz et al, 2010;
Temkin et al, 2010; Oza et al, 2011a). Ridaforolimus has also been
evaluated in multiple clinical trials, with antitumor activity seen in
a variety of solid and haematologic malignancies (Mita et al, 2008;
Rizzieri et al, 2008; Chawla et al, 2012; Seki et al, 2012). Preclinical
studies with ridaforolimus demonstrated antiproliferative activity
in endometrial tumour cell lines AN3CA and HEC-1B (Squillace
et al, 2011). In a phase 1 clinical trial, treatment with ridaforolimus
resulted in prolonged partial response (PR) in a patient with mixed
Müllerian uterine cancer (Mita et al, 2008). Here we describe
results from a phase 2 trial designed to assess the efficacy and
safety of intravenously administered single-agent ridaforolimus in
patients with recurrent or persistent endometrial cancer.
MATERIALS AND METHODS
Study design. This was a phase 2, open-label, single-arm,
multicentre study with planned enrolment of approximately 44
patients at nine centres in the United States and Europe (http://
clinicaltrials.gov/ct2/show/NCT00122343; Protocol 019). Intrave-
nous ridaforolimus was administered at a fixed dose of 12.5 mg
over 30 min once daily for 5 consecutive days every 2 weeks, with
each treatment cycle defined as a 4-week period (i.e., two courses of
ridaforolimus). This intravenous dose was identified as the
recommended phase 2 dose in a previous phase 1 trial of
ridaforolimus in patients with advanced malignancies (Mita et al,
2008). Patients were scheduled to receive 2–6 cycles of treatment,
but were allowed to continue treatment with ridaforolimus if they
maintained at least stable disease (SD) and acceptable tolerability.
Consistent with other phase 2 trials in this clinical setting, palliative
and supportive care were permitted during the study, but
concurrent treatment with other anticancer modalities was
prohibited. Other investigational drugs or devices were also
prohibited, as were herbal preparations or related over-the-counter
preparations containing herbal ingredients known to affect
cytochrome P450-3A isoenzymes (e.g., St John’s wort). Patients
were followed on study for 24 months after their last dose of
ridaforolimus.
The study protocol and patient informed consent forms were
approved by each local institutional review board or independent
ethics committee before patients were enroled. The study was
conducted in accordance with the ethical principles originating in
the Declaration of Helsinki, and in compliance with International
Conference on Harmonisation, Good Clinical Practices, and
regulatory guidelines.
Patients. Women aged 18 years or older with histologically
confirmed endometrial cancer who had recurrent or persistent
disease and documented disease progression (within 3 months
before entry) were eligible if they had at least one measurable lesion
based on Response Evaluation Criteria in Solid Tumours (RECIST)
guidelines (Eisenhauer et al, 2009); Eastern Cooperative Oncology
Group performance status 0–2; minimum expected life expectancy
of 3 months; and adequate renal, hepatic, and bone marrow
function. Patients were to be excluded if they had received more
than two prior regimens of cytotoxic chemotherapy or targeted
therapy – patients could have undergone surgery and/or received
prior radiotherapy and still be included in the study. Patients who
had received any therapy with rapamycin or a rapamycin analogue
were also excluded. Other exclusion criteria were the presence of
brain metastases, anticancer treatment within 4 weeks before the
first dose of ridaforolimus (X6 weeks for nitrosourea or
mitomycin), ongoing toxicity associated with prior anticancer
therapy, another primary malignancy within 3 years of the trial
(except for non-melanoma skin cancer), uncontrolled cardiovas-
cular disease, or active infection requiring systemic therapy.
Pregnant or lactating women were also excluded.
Trial end points and assessments. The primary end point was the
clinical benefit response (CBR), defined as a complete response or
PR or prolonged SD lasting at least 16 weeks as assessed by
modified the RECIST 1.0 criteria. Secondary end points of the trial
included progression-free survival (PFS), safety, and tolerability.
Time to disease progression, overall survival, and duration of
response were planned secondary analyses but were not performed
in the trial. Target and non-target lesions were assessed at baseline
and after every two cycles (8 weeks) of ridaforolimus therapy.
Patients received treatment with ridaforolimus until disease
progression or other discontinuation criteria were met. Safety
was assessed by routine physical and laboratory evaluations.
Patients were monitored for adverse events (AEs) and disease
progression throughout the study and at follow-up visits up to 24
months after the last dose of ridaforolimus. All study drug-related
AEs were followed until resolution or until administration of
another anticancer therapy.
Statistical analyses. This study used Simon’s optimal two-stage
design, which was formulated to distinguish a favourable true CBR
rate of X35% from a null rate of p15% with 90% power, at a
significance level of 0.05. In total, 19 patients were to be enroled in
the first stage. Further enrolment was to be discontinued if CBRs
were observed in three or fewer of the first 19 patients. However, if
four or more patients achieved CBRs, 25 additional patients were
to be enroled. The regimen was to be considered effective if a CBR
rate of 25% or greater was observed (i.e., 11 or more CBRs among
44 patients).
All patients receiving at least one dose of ridaforolimus
comprised the intent-to-treat (ITT) population, and all were
assessed for safety. The severity of AEs was graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE, version 3.0). The frequency of AEs
categorised by severity grades and changes in laboratory tests were
evaluated using descriptive statistics.
RESULTS
Patient baseline characteristics and disposition. A total of 45
patients, with a median age of 66.7 (range: 28–89) years, were
enroled in the trial and received at least one dose of ridaforolimus
(Table 1). The majority of patients had endometrioid adenocarci-
noma (64%); 22% had serous tumours, and 11% had carcinosar-
comas. Most patients had metastatic disease in lymph nodes (56%)
or in the lung (51%). The study population was heavily pretreated,
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with 26 patients (56%) having received two prior systemic
regimens. In addition, a protocol violation occurred (as patients
with two or more prior cytotoxic chemotherapy or targeted therapy
regimens were excluded from the study): three patients (7%)
received three or more prior systemic regimens. Ridaforolimus was
administered for a median duration of 61 days (range: 1–425 days)
and at a median cumulative dose of 250 mg (range: 12.5–1750 mg).
All patients had discontinued ridaforolimus by the time of the
analysis. In all, 33 patients (73%) were taken off this protocol
owing to documented progressive disease, four patients (8%) were
taken off this protocol owing to AEs (of which one was considered
by the investigator to be related study treatment), four patients
(8%) made a voluntary decision to stop treatment (i.e., withdrew
consent), and the remaining four patients (8%) discontinued at the
discretion of the investigator.
Efficacy. Of the 45 patients in the ITT population, 13 (29%)
achieved CBR, including 5 (11%) with confirmed PR and 8 (18%)
with SD lasting 16 weeks or longer (Table 2). Clinical benefit
response was achieved in 10 of 29 patients (34%) with
endometrioid tumours, in 2 of 10 patients (20%) with papillary
serous carcinomas, and in the lone patient with mixed epithelial
histology. None of the five patients with carcinosarcomas had a
CBR. Overall, the 13 patients who achieved a CBR received
ridaforolimus for more than 4 months (Figure 1). The efficacy of
ridaforolimus is illustrated by the case of a 59-year-old woman
diagnosed with papillary serous endometrial cancer with multiple
metastases, who achieved a confirmed PR after four cycles of
therapy (Figure 2). A waterfall plot of the best overall response
from baseline for each patient is shown in Figure 3. The 6-month
PFS was determined to be 18% following treatment with
ridaforolimus.
Safety. All patients had at least one AE regardless of relationship
to study treatment. The most common AEs were mouth sores
(stomatitis and mucosal inflammation), anaemia, fatigue, diar-
rhoea, nausea, and vomiting (Table 3). Treatment-related AEs
occurred in 42 patients (93%); the most common were mouth sores
(56%), anaemia (42%), fatigue (40%), diarrhoea (31%), nausea
(29%), vomiting (27%), asthenia (24%), and anorexia (22%). In
total, 23 patients (51%) experienced serious AEs (SAEs), with seven
patients (16%) having SAEs attributable, by the investigator, to
treatment. These included three patients with anaemia (two with
grade 3 and one with grade 2) and individual patients with
deep vein thrombosis (grade 3), vomiting (grade 2), dehydration
(grade 3), and stomatitis (grade 2). Each of these events was self-
limiting except for one case of anaemia that led to clinical sequelae.
A total of 15 patients (33%) experienced at least one treatment-
related AE that led to a dose modification. One patient (2%)
discontinued treatment with ridaforolimus owing to a treatment-
related AE (grade 3 worsening of interstitial lung disease) and three
additional patients (7%) discontinued treatment owing to AEs not
attributed to study drug (grade 2 infection; grade 3 sepsis; and
grade 3 mood alteration, respectively).
None of the patients died during treatment with ridaforolimus.
In all, 24 patients (53%) died during the follow-up period after
ridaforolimus was discontinued, including four patients (17%) who
died within 30 days of receiving the last dose of ridaforolimus. All
four of these deaths were due to progressive disease.
DISCUSSION
Patients with endometrial cancers in the second-line setting or
beyond have few effective treatment options. This phase 2 clinical
trial demonstrates that single-agent ridaforolimus has antitumor
activity in women with advanced endometrial cancer, most of
whom had received two prior chemotherapy regimens. The study





Mean (s.d.) 66.1 (10.4)
Median 66.7
Range 28–89




Tumour histology, n (%)
Endometrioid 28 (62)
Papillary serous 10 (22)
Mixed epithelial 1 (2)
Carcinosarcoma or MMMT 5 (11)
Location or organ with metastatic disease, n (%)a





Ascites (non-measurable) 6 (13)
Peritoneum 5 (11)




3 or more 3 (7)
Missing 2 (4)
Radiotherapy 30 (67)
Surgical therapy 44 (98)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; MMMT¼malignant mixed
Müllerian tumour; s.d.¼ standard deviation.
aPercentages may add up to more than 100%, as a patient may have more than one site of
disease.
Table 2. Tumour response rates based on RECIST guidelines
Best response with
ridaforolimus, n (N¼45)
Tumour histology CR PR SDa
Endometrioid (n¼28) 0 3 7
Papillary serous (n¼ 10) 0 1 1
Mixed epithelial (n¼ 1) 0 1 0
Carcinosarcoma or MMMT (n¼ 5) 0 0 0
Total, n (%) 0 5 (11) 8 (18)
Abbreviations: CR¼ complete response; MMMT¼malignant mixed Müllerian tumour;
PR¼partial response; RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼ stable
disease.
aSD for a duration of at least 16 weeks.
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met its primary end point, as 29% of patients achieved a CBR (11%
confirmed PR, 18% SD lasting 16 weeks or longer), thereby
exceeding the Simon 2-stage criteria (i.e., CBR rate X25%)
established for efficacy. Ridaforolimus also showed an acceptable
toxicity profile with the most common AEs (e.g., mouth sores,
anaemia, and fatigue) being predictable, manageable, and con-
sistent with those observed in previous trials with ridaforolimus
and in studies with other mTOR inhibitors (Dancey and Monzon,
2011; Pilotte et al, 2011). One-third of the patients had treatment-
related AEs that led to dose delay or reduction. Four patients were
taken off protocol owing to AEs, but in only one case the AE was
considered by the investigator to be treatment related.
Several other mTOR inhibitors have been investigated in
women with advanced endometrial cancer. In a recently published
phase 2 study among patients with recurrent endometrial
carcinoma treated with a 10-mg oral daily dose of everolimus,
6 of 28 evaluable patients (21%) achieved a CBR; fatigue, anaemia,
pain, lymphopenia, and nausea were reported as the most common
AEs (Slomovitz et al, 2010). In another phase 2 trial, treatment
with 25 mg intravenous temsirolimus administered weekly as
monotherapy to patients with recurrent or metastatic endometrial
cancer produced confirmed PRs in 4 of 29 chemotherapy-naı̈ve
evaluable patients (14%) and 1 of 25 evaluable patients (4%) who
had been previously treated with chemotherapy (Oza et al, 2011a).
The chemotherapy-naı̈ve subset also had higher SD rates with
longer median response duration than the chemotherapy-treated
subset. Median PFS was 7.3 months in the chemotherapy-naı̈ve
group compared with 3.3 months in the chemotherapy-treated
group. The most common AEs reported with temsirolimus were
pneumonitis, mucositis, fatigue, gastrointestinal disorders, and
pain.
The results of this study with ridaforolimus combined with the
findings of the earlier phase 2 studies with everolimus and
temsirolimus suggest that mTOR inhibitors have single-agent
clinical benefit in advanced and recurrent endometrial cancer.
Unfortunately, predictive factors have not yet been identified to
select patients most likely to benefit from mTOR inhibitor therapy.
For example, in a phase 2 trial with temsirolimus, loss of PTEN
and other molecular markers of the PI3K/AKT/mTOR pathway
did not appear to correlate with clinical outcomes (Oza et al,
2011a). Similarly, in a preclinical setting (i.e., fresh endometrial
cancer tumour explants), PTEN and AKT status did not predict the
antiproliferative effects of rapamycin (Bae-Jump et al, 2010).
Predictive markers were not evaluated in this study owing to the
limited availability of archival and biopsy tumour specimens in the
study cohort.
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Figure 1. Time on trial with ridaforolimus.
Baseline Cycle 2 Cycle 4
Figure 2. Patient aged 59 years with papillary serous endometrial cancer with multiple metastases treated with ridaforolimus. Baseline scan
revealed a 2523 mm mass in the right lung, which decreased to 14 13 mm after cycle 2 of therapy, and by cycle 4 was confirmed as a PR by
RECIST guidelines.
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The profile of mTOR inhibitors as monotherapy suggests that
they may be amenable for use in combination with other active
agents. In support of this approach, rapamycin showed synergistic
effects in vitro in endometrial cancer cell lines when tested in
combination with paclitaxel or cisplatin (Bae-Jump et al, 2009;
Shafer et al, 2010). The clinical significance of these findings remains
to be determined, along with careful evaluation of the tolerability of
mTOR inhibitor–chemotherapy combinations. Temsirolimus was
evaluated in combination with topotecan in women with advanced
gynaecologic tumours, including endometrial cancer, in a phase 1
study; the combination was successful in treating a subset of patients
without prior pelvic radiotherapy, but it was not tolerated in patients
with prior pelvic radiotherapy (Temkin et al, 2010).
The results of this study indicate that ridaforolimus has
antitumor activity in women with advanced or recurrent endome-
trial cancer. Studies with both intravenous (ridaforolimus and
temsirolimus) and oral (everolimus) formulations of mTOR
inhibitors have demonstrated clinical benefit in this patient
population. No differences in treatment outcomes have been
formally investigated between intravenous and oral formulations.
Therefore, with similar clinical benefits and safety profiles observed
across the mTOR studies, administration of an oral formulation
would most likely be preferred by patients and their treating
physicians. Preliminary results of a phase 2 trial testing the oral
formulation of ridaforolimus, administered at 40 mg per day once
daily for 5 days followed by a 2-day rest period, suggest that orally
administered ridaforolimus is also effective in women with advanced
endometrial cancer (Oza et al, 2011b). On the basis of these findings,
mTOR inhibition with ridaforolimus is a potential therapeutic
option in endometrial cancer and warrants further study as a single
agent or in combination with other agents. Future studies evaluating
predictive biomarkers will also provide critical data to help identify
patients who may benefit from treatment with mTOR inhibitors.
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Figure 3. Waterfall plot showing distribution of the best percentage change in target lesion size from baseline for an individual patient (n¼ 35; not
evaluable, n¼10). The lines (–30 and þ20%) indicate the region with change from baseline that typically represent SD based on RECIST
guidelines.
Table 3. Treatment-related adverse events experienced by eight or more
patients, and all grade 3/4 events reported following treatment with
ridaforolimus
Ridaforolimus (N¼45)
Adverse event, n (%)a All grades Grade 3/4
Mouth soresb 25 (56) 4 (9)
Anaemia 19 (42) 10 (22)
Fatigue 18 (40) 2 (4)
Diarrhoea 14 (31) 0
Nausea 13 (29) 2 (4)
Vomiting 12 (27) 1 (2)
Asthenia 11 (24) 2 (4)
Anorexia 10 (22) 1 (2)
Dysgeusia 8 (18) 0
Anorexia 10 (22) 1 (2)
Hyperglycaemia 5 (11) 4 (9)
Hypertriglyceridaemia 5 (11) 2 (4)
Hypokalaemia 5 (11) 1 (2)
aIf multiple episodes of an event are experienced by one patient, the patient/event is
presented once at the highest grade reported.
bIncludes stomatitis and mucosal inflammation.
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